ESE
E-mail Alert |
May
2006 |
 |
Headlines
|
Contents
|
|
Latest News
from ESE |
|
ECE 2007
Further details about ECE 2007 will
be available shortly on the congress
website: www.ece2007.com. Why not put
your name down to receive further details
about registration, social/optional tours
and prices, by clicking on the link below.
Pre-Registration
|
Update on ESE Membership
ESE memerbship numbers continue to climb
and the latest figures show that there
are now nearly 800 members. To join from
only €25, and to find out more about
the benefits of joining click on the
link below.
ESE
Membership
|
Reduced Subscription Rates for ESE
Official Journals
In addition to the European Journal
of Endocrinology, the Journal
of Endocrinology, Journal of Molecular
Endocrinology & Endocrine-Related
Cancer are all now official ESE
journals. Reduced subscription rates
are available to all members of the
ESE. Details of rates can be found
on the Journals page of the website.
Click
Here
|
ESE Constitution now available online
The transformation of ESE from Federation
to Society is continuing and the Constitution
documents are now available to view online.
Keep up to date with the latest developments
by checking the website.
Constitution
ESE
Website
|
|
|
European News |
|
A gene predisposing to pituitary tumors
identified (University of Helsinki, 26
May 2006)
A recent Finnish study identifies a
low-penetrance gene defect which predisposes
carriers to intracranial tumors called
pituitary adenomas. In particular individuals
carrying the gene defect are susceptible
to such tumors which secrete growth hormone.
Excess of growth hormone results in conditions
called acromegaly and gigantism.
Identification of this gene defect using
DNA-chip technologies is an example of
how genetic research can tackle more
and more demanding tasks, such as identification
of predisposition genes conferring a
low absolute but high relative risk.
The results were published in the May
26 issue of the journal Science.
http://www.sciencemag.org/cgi/reprint/312/5777/1228.pdf
|
American Endocrine Society publishes
Clinical Guidelines
The Endocrine Society has published
the first in a series of clinical guidelines
in endocrinology created to help physicians
based around the world. The first; Evaluation
and Treatment of Adult Growth Hormone
Deficiency appeared in the May issue
of The Journal of Clinical Endocrinology & Metabolism
and has been followed with Testosterone
Therapy in Adult Men with Androgen Deficiency
Syndromes in the June issue. Upcoming
guidlines will include: Therapeutic
Use of Androgens in Women, Prevention
and Treatment of Paediatric Obesity,
Management of Thyroid Dysfunction During
Pregnancy and Postpartum, and The
Metabolic Syndrome. The Growth Hormone
and Testosterone guidelines can now be
found on their website or by following
the links below.
Growth Hormone Guidelines
Testosterone Guidelines
|
Sunscreens: Never 100% protection -
Commission consults on product labelling
When we are in the sun, we expose ourselves
to two different types of hazardous UV-radiation
- UVA and UVB radiation. UVB radiation
is the cause for "sun-burn". UVA radiation
causes premature skin ageing, interferences
with the human immune system, and is
an important contributor to the skin-cancer
risk. Yet how many people know that the
'sun protection factor' in sunscreens
only protects against sunburn (UVB radiation)?
The European Commission has launched
a public consultation. It intends to
use the results of this consultation
to publish non-binding guidelines for
producers setting minimum standards for
sunscreen products and ensure a simple,
understandable labelling. The text is
available for comments on the Europa
website.
Link
|
Commission study addresses Europe's
scientific publication system: DEADLINE
EXTENDED
The European Commission has published
a study which examines the scientific
publication system in Europe and have
extended their deadline for feedback
to 15th June 2006. The report,
drawn up for the Commission by a panel
of experts, makes a number of recommendations
for future action, including improving
access to publicly-funded research. All
interested parties are invited to send
feedback on the report's findings to
the Commission, to provide input for
a conference on scientific publication
to be held in autumn 2006. You can add
your contributions online in SINAPSE
by entering the Community on SCIENTIFIC
PUBLICATIONS ("Your communities" on the
left menu) and the consultation hosted
in the "Discussions & surveys" module.
PLEASE NOTE: you have to be a member
to access this area of the website. Contributions
should be sent to rtd-scientific-publication@cec.eu.int
by 15th June 2006. SINAPSE, the web interface
between the scientific community and
Europe's policy-makers, will also host
a debate on the subject.
Sinapse Website
|
|
|
What's Hot in EJE? |
|
Healthcare utilization, quality of
life and patient-reported outcomes during
two years of GH replacement therapy in
GH-deficient adults - comparison between
Sweden, The Netherlands and Germany
Bernhard Saller, Anders F Mattsson,
Peter H Kann, Hans P Koppeschaar, Johan
Svensson, Marjolein Pompen and Maria
Kołtowska-Häggström
The beneficial effects of growth hormone
(GH) replacement therapy in hypopituitary
adults with GH deficiency are well known.
Long-term follow-up of the outcomes of
GH replacement therapy, using multinational
data, has confirmed that these benefits
(improved quality of life (QoL) and reduced
utilisation of healthcare) are also not
short-lived. But are these patterns representative
of all countries, which employ varying
types of healthcare system and have diverse
patient population characteristics? A
single country analysis of Sweden suggests
they are. Now, Saller and colleagues
assess the effects of GH replacement
therapy on QoL and healthcare utilisation
over 2 years in three different European
Countries - Sweden, The Netherlands and
Germany.
Their findings confirm the patterns
seen in both the multinational and single
country data - QoL improves and is maintained
over the course of GH replacement therapy,
while the utilisation of healthcare declines.
These measures changed to similar extents
in all three countries. Improvement in
QoL was associated with increased physical
activity, patient-reported improvement
in health and the reduced need for help
in everyday activities. No link was found
between reduced healthcare utilisation
and improved QoL.
This study presents a useful comparative
analysis of the trends in these measures
in three distinct European populations,
emphasising their reliability and providing
an important reference for future socioeconomic
evaluations of GH replacement in Western
Europe.
EJE 154-6 pp843-850
|
|
|
Jobs, Grants and Prizes |
|
Exploratory Grant Program in Diabetes
Endocrinology and Metabolism (NIH)
The Division of Diabetes, Endocrinology,
and Metabolic Diseases of the National
Institute of Diabetes and Digestive and
Kidney Diseases invites applications
for the exploratory/developmental (R21)
grant mechanism in selected areas of
opportunity within our mission. Various
closing dates, follow the link below
for more details.
Full Details
|
Pilot and Feasibility Clinical Research
Grants in Diabetes, Endocrine and Metabolic
Diseases (NIH)
The Pilot and Feasibility Clinical Research
Grants Program is designed to support
short-term clinical pilot studies and
planning activities to help stimulate
the translation of promising research
developments from the laboratory into
clinical practice for diabetes, endocrine
and metabolic diseases. Various Closing
dates, follow the link below fore more
details.
Full Details
|
Specialised Cooperative Centres Program
In Reproduction And Infertility Research
(NIH)
The National Institute of Child Health
and Human Development (NICHD) provides
funding for a limited number of research
centres in the reproductive sciences.
These centres provide an arena for multidisciplinary
interactions among basic and clinical
scientists interested in establishing
high quality programs in reproduction
and infertility research. The centres
will also serve as national resources
for the training and career development
of new scientists electing to pursue
research in high priority areas of reproduction
and infertility research. The purpose
of this RFA is to announce the annual
recompetition of the Specialized Cooperative
Centres Program in Reproduction Research
now called the Specialized Cooperative
Centres Program in Reproduction and Infertility
Research. The benefit of this activity
will be to the infertile couples, their
health-care providers, and the public.
Release Date: January 19, 2006
Expiration Date: August 12, 2006
http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-06-005.html
|
First Authored Student Award for Endocrinology
and Molecular Endocrinology (RD Info)
The Endocrine Society presents awards
for outstanding first authored student
papers published in Endocrinology and
Molecular Endocrinology. Endocrinology
and Molecular Endocrinology sponsor two
awards each per year. Awardees receive
a $1,000 (approx €830) award and
free registration to the annual Endocrine
Society meeting in June. Apply anytime.
Full Details
|
Funding opportunities for Endocrine
Disrupting on the EUROPA website
Keep a look out for new opportunies
on the EUROPA website: http://europa.eu.int/comm/research/endocrine/projects_opportunities_en.html
|
NIH Grants
See all grants & finding opportunities
at http://grants1.nih.gov/grants/index.cfm
|
Funding opportunities on the RDInfo
website
www.rdinfo.org.uk
|
|
|
Commercial
News |
|
Biopartners Receives European Union
Marketing Authorisation for its Biosimilar
Recombinant Human Growth Hormone - Valtropin
BAAR, Switzerland, May 4, 2006 - Biopartners,
a privately-owned biopharmaceuticals
company has received marketing authorisation
for the European Union from the European
Commission for its biosimilar medicinal
product Valtropin, a recombinant human
growth hormone used for the treatment
of human growth deficiency in children
and Turner's Syndrome.
Full story
|
|
|
ESE Conferences
and Courses |
|
|
|
World Calendar |
|
|
|
 |